Inflammation and Parkinson's disease pathogenesis
Identifieur interne : 003724 ( Istex/Corpus ); précédent : 003723; suivant : 003725Inflammation and Parkinson's disease pathogenesis
Auteurs : Serge PrzedborskiSource :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
Abstract
Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22638
Links to Exploration step
ISTEX:E9EFAE6C04F827D7F710F0D12104E4DD2321437CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inflammation and Parkinson's disease pathogenesis</title><author><name sortKey="Przedborski, Serge" sort="Przedborski, Serge" uniqKey="Przedborski S" first="Serge" last="Przedborski">Serge Przedborski</name><affiliation><mods:affiliation>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E9EFAE6C04F827D7F710F0D12104E4DD2321437C</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22638</idno><idno type="url">https://api.istex.fr/document/E9EFAE6C04F827D7F710F0D12104E4DD2321437C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003724</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inflammation and Parkinson's disease pathogenesis</title><author><name sortKey="Przedborski, Serge" sort="Przedborski, Serge" uniqKey="Przedborski S" first="Serge" last="Przedborski">Serge Przedborski</name><affiliation><mods:affiliation>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S55">S55</biblScope><biblScope unit="page" to="S57">S57</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E9EFAE6C04F827D7F710F0D12104E4DD2321437C</idno><idno type="DOI">10.1002/mds.22638</idno><idno type="ArticleID">MDS22638</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>Parkinson's disease</term><term>inflammation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Serge Przedborski MD, PhD</name><affiliations><json:string>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>inflammation</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>2.812</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>571</abstractCharCount><pdfWordCount>1888</pdfWordCount><pdfCharCount>12430</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>77</abstractWordCount></qualityIndicators><title>Inflammation and Parkinson's disease pathogenesis</title><genre><json:string>Serial article</json:string></genre><host><volume>25</volume><pages><total>3</total><last>S57</last><first>S55</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><author><json:item><name>Fahn Stanley MD</name></json:item><json:item><name>Marder Karen MD</name></json:item><json:item><name>Côté Lucien MD</name></json:item><json:item><name>Reich Stephen G. MD</name></json:item></author><subject><json:item><value>Pathogenesis and Implications for Neuroprotection</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22638</json:string></doi><id>E9EFAE6C04F827D7F710F0D12104E4DD2321437C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E9EFAE6C04F827D7F710F0D12104E4DD2321437C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E9EFAE6C04F827D7F710F0D12104E4DD2321437C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E9EFAE6C04F827D7F710F0D12104E4DD2321437C/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Inflammation and Parkinson's disease pathogenesis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>NIH/NINDS - No. RO1 AG21617; No. P01 NS11766‐27A1;</note><note>Udall Parkinson's Disease Research - No. P50 NS38370;</note><note>US Department of Defense - No. DAMD 17‐03‐1;</note><note>MDA/Wings Over Wall Street</note><note>Parkinsons Disease Foundation, USA</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Inflammation and Parkinson's disease pathogenesis</title><author><persName><forename type="first">Serge</forename><surname>Przedborski</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: BB‐302, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032</p></note><affiliation>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010"></date><biblScope unit="vol">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S55">S55</biblScope><biblScope unit="page" to="S57">S57</biblScope></imprint></monogr><idno type="istex">E9EFAE6C04F827D7F710F0D12104E4DD2321437C</idno><idno type="DOI">10.1002/mds.22638</idno><idno type="ArticleID">MDS22638</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>MPTP</term></item><item><term>inflammation</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Pathogenesis and Implications for Neuroprotection</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-03-22">Received</change><change when="2009-03-27">Registration</change><change when="2010">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E9EFAE6C04F827D7F710F0D12104E4DD2321437C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="5"><doi origin="wiley" registered="yes">10.1002/mds.v25.1s</doi><titleGroup><title type="specialIssueTitle">Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">S1</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Fahn</givenNames><familyName>Stanley</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Marder</givenNames><familyName>Karen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Côté</givenNames><familyName>Lucien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped4" creatorRole="sponsoringEditor"><personName><givenNames>Reich</givenNames><familyName>Stephen G.</familyName><degrees>MD</degrees></personName></creator></creators><coverDate startDate="2010">2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22638</doi><idGroup><id type="unit" value="MDS22638"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Pathogenesis and Implications for Neuroprotection</title><title type="tocHeading1">Pathogenesis and Implications for Neuroprotection</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-03-22"></event><event type="manuscriptAccepted" date="2009-03-27"></event><event type="firstOnline" date="2010-02-25"></event><event type="publishedOnlineFinalForm" date="2010-02-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S55</numbering><numbering type="pageLast">S57</numbering></numberingGroup><correspondenceTo>BB‐302, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22638.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="1988"></count></countGroup><titleGroup><title type="main" xml:lang="en">Inflammation and Parkinson's disease pathogenesis<link href="#fn1"></link></title><title type="short" xml:lang="en">Inflammation, Parkinson's Disease Pathogenesis</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Serge</givenNames><familyName>Przedborski</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>SP30@Columbia.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">MPTP</keyword><keyword xml:id="kwd3">inflammation</keyword></keywordGroup><fundingInfo><fundingAgency>NIH/NINDS</fundingAgency><fundingNumber>RO1 AG21617</fundingNumber><fundingNumber>P01 NS11766‐27A1</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Udall Parkinson's Disease Research</fundingAgency><fundingNumber>P50 NS38370</fundingNumber></fundingInfo><fundingInfo><fundingAgency>US Department of Defense</fundingAgency><fundingNumber>DAMD 17‐03‐1</fundingNumber></fundingInfo><fundingInfo><fundingAgency>MDA/Wings Over Wall Street</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Parkinsons Disease Foundation, USA</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Inflammation and Parkinson's disease pathogenesis</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Inflammation, Parkinson's Disease Pathogenesis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Inflammation and Parkinson's disease pathogenesis</title></titleInfo><name type="personal"><namePart type="given">Serge</namePart><namePart type="family">Przedborski</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA</affiliation><description>Correspondence: BB‐302, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010</dateIssued><dateCaptured encoding="w3cdtf">2008-03-22</dateCaptured><dateValid encoding="w3cdtf">2009-03-27</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">25</extent><extent unit="words">1988</extent></physicalDescription><abstract lang="en">Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial‐derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">NIH/NINDS - No. RO1 AG21617; No. P01 NS11766‐27A1; </note><note type="funding">Udall Parkinson's Disease Research - No. P50 NS38370; </note><note type="funding">US Department of Defense - No. DAMD 17‐03‐1; </note><note type="funding">MDA/Wings Over Wall Street</note><note type="funding">Parkinsons Disease Foundation, USA</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>MPTP</topic><topic>inflammation</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Fahn</namePart><namePart type="family">Stanley</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Marder</namePart><namePart type="family">Karen</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Côté</namePart><namePart type="family">Lucien</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Reich</namePart><namePart type="family">Stephen G.</namePart><namePart type="termsOfAddress">MD</namePart></name><subject><genre>article category</genre><topic>Pathogenesis and Implications for Neuroprotection</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="title"><title>Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><extent unit="pages"><start>S55</start><end>S57</end><total>3</total></extent></part></relatedItem><identifier type="istex">E9EFAE6C04F827D7F710F0D12104E4DD2321437C</identifier><identifier type="DOI">10.1002/mds.22638</identifier><identifier type="ArticleID">MDS22638</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003724 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003724 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E9EFAE6C04F827D7F710F0D12104E4DD2321437C
|texte= Inflammation and Parkinson's disease pathogenesis
}}
| This area was generated with Dilib version V0.6.23. |  |